Panacea Biotec shines on launching fully-liquid wP-IPV based Pentavalent vaccine `EasyFourPol`
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Panacea Biotec is currently trading at Rs. 170.40, up by 7.40 points or 4.54% from its previous closing of Rs. 163.00 on the BSE.
The scrip opened at Rs. 170.40 and has touched a high and low of Rs. 177.75 and Rs. 169.65 respectively. So far 25659 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 181.95 on 18-Oct-2023 and a 52 week low of Rs. 107.15 on 29-Mar-2023.
Last one week high and low of the scrip stood at Rs. 177.75 and Rs. 162.40 respectively. The current market cap of the company is Rs. 998.39 crore.
The promoters holding in the company stood at 73.59%, while Institutions and Non-Institutions held 0.83% and 25.58% respectively.
Panacea Biotec has launched world's first fully-liquid wP-IPV based Pentavalent vaccine, EasyFourPol, in India and received registration of Valganciclovir 50 mg/ml Powder for Oral Solution by its step-down wholly-owned subsidiary company viz. Panacea Biotec Germany GmbH, in Germany. EasyFourPol is the world's first fully liquid wP-IPV Pentavalent vaccine. wP-IPV Pentavalent vaccine protects children against five deadly diseases: Diphtheria, Tetanus, Pertussis, Polio, and invasive infections caused by Haemophilus Influenza Type b.
EasyFourPol is a ready-to-use combination vaccine that does not require preparation by healthcare workers at the clinic. It achieves the same level of protection as immunized with single-antigen vaccines, reduces the number of visits to vaccination centres, and reduces the overall cost of immunisation for all stakeholders. It leads to less vaccination and lesser shots for the child and greater comfort for the parents while ensuring better compliance for healthcare practitioners. Fewer shots also mean time saved for parents and more efficiency at points of vaccination. Additionally, it also helps reduce carbon emissions by reducing the need for vials, syringes, packaging material, and visits to vaccine administration centres.
Panacea Biotec is a leading research based Biotechnology Company with established research, manufacturing and marketing capabilities.
